ATRA and Carfilzomib for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests if combining the drug ATRA with carfilzomib can help people with multiple myeloma whose cancer has come back or stopped responding to at least three prior treatments, including carfilzomib. The goal is to see if this new combination works better than carfilzomib alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have multiple myeloma that has returned or is not responding to treatment.
- You have tried at least three prior treatments, including drugs like lenalidomide or pomalidomide, carfilzomib or bortezomib, and daratumumab or isatuximab.
- Your cancer continued to grow or did not shrink enough after at least two cycles of a carfilzomib-based treatment.
- You are able to get around and take care of yourself (ECOG score 0, 1, or 2).
- Your kidney, liver, and heart functions are adequate, and your blood counts are within a certain range.
- You have measurable signs of myeloma in your blood or urine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of four drugs for people with high-risk multiple myeloma that has come back or did not respond to initial treatment. The goal is to see if this combination is safe and effective.
This Phase 1 study tests a carfilzomib-based treatment plan to help people with multiple myeloma collect enough stem cells for an autologous (using your own) stem cell transplant. It’s mainly about whether this mobilization approach works and is safe for you.
This trial tests a combination of the drugs daratumumab, carfilzomib, lenalidomide, and dexamethasone given before and after a stem cell transplant for people with ultra high-risk multiple myeloma. The goal is to see if this regimen is safe and more effective than standard treatments.
This trial tests a new kind of CAR-T cell therapy (called APRIL-BAFF-Bicephali CAR-T) for people with multiple myeloma that has come back or not responded to treatment. It aims to see if this therapy is safe and can help when other treatments have stopped working.
This trial tests a new treatment that combines a stem cell transplant with special immune cells (called CAR-T cells) to fight multiple myeloma. The goal is to see if this combined approach helps people with newly diagnosed myeloma achieve better control of their disease.
This trial is testing a combination of three drugs (carfilzomib, cyclophosphamide, and dexamethasone) for people with multiple myeloma that has come back or stopped responding to previous treatments, especially if they've already had lenalidomide. The goal is to see if this combination can help control the cancer.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.